Review
doi: 10.1097/IGC.0b013e31821b2568.
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference
Affiliations
- PMID: 21543936
- DOI: 10.1097/IGC.0b013e31821b2568
Item in Clipboard
Review
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference
Int J Gynecol Cancer.
2011 May.
Abstract
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer. This report provides the outcomes from the Fourth Ovarian Cancer Consensus Conference.
Similar articles
-
The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.Int J Gynecol Cancer. 2011 May;21(4):746-9. doi: 10.1097/IGC.0b013e31821bb446. Int J Gynecol Cancer. 2011. PMID: 21543935
-
American Society of Clinical Oncology 2012 Annual Meeting: highlights from the gynecologic oncology track.Int J Gynecol Cancer. 2012 Nov;22(9):1634-9. doi: 10.1097/IGC.0b013e318270febe. Int J Gynecol Cancer. 2012. PMID: 23095779
-
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8. doi: 10.1097/IGC.0000000000000282. Int J Gynecol Cancer. 2014. PMID: 25341581 Review.
-
Clinical trials in recurrent ovarian cancer.Int J Gynecol Cancer. 2011 May;21(4):771-5. doi: 10.1097/IGC.0b013e31821bb8aa. Int J Gynecol Cancer. 2011. PMID: 21543939 Review.
-
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S61-6. doi: 10.1097/IGC.0000000000000261. Int J Gynecol Cancer. 2014. PMID: 25341583 Free PMC article. Review.
Cited by
-
Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer-Quality of Life Evaluation Research) Prospective, International, Multicentre Study.Cancers (Basel). 2023 Dec 22;16(1):75. doi: 10.3390/cancers16010075. Cancers (Basel). 2023. PMID: 38201503 Free PMC article.
-
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.Ther Adv Med Oncol. 2023 Nov 22;15:17588359231208674. doi: 10.1177/17588359231208674. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38028140 Free PMC article.
-
FT-Raman data analyzed by multivariate and machine learning as a new methods for detection spectroscopy marker of platinum-resistant women suffering from ovarian cancer.Sci Rep. 2023 Nov 26;13(1):20772. doi: 10.1038/s41598-023-48169-3. Sci Rep. 2023. PMID: 38008780 Free PMC article.
-
Rationale and Methodologic Approach for Assessing Ovarian Cancer Treatment and Gynecologic Oncologist Involvement in the Midwest Region of the United States.J Registry Manag. 2023 Fall;50(3):85-91. J Registry Manag. 2023. PMID: 37941740 Free PMC article.
-
Heterogeneity and treatment landscape of ovarian carcinoma.Nat Rev Clin Oncol. 2023 Dec;20(12):820-842. doi: 10.1038/s41571-023-00819-1. Epub 2023 Oct 2. Nat Rev Clin Oncol. 2023. PMID: 37783747 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
